A patient with co-occurring major depression and opioid use disorder is started on buprenorphine/naloxone. Which additional benefit of this medication is particularly relevant to this patient's psychiatric comorbidity?
-
A
Buprenorphine has no psychotropic effects beyond addiction treatment
-
B
Buprenorphine has demonstrated antidepressant properties through kappa-opioid receptor antagonism
-
C
Naloxone component treats depression independently
-
D
Buprenorphine increases serotonin levels equivalent to SSRIs